Targeting the mTOR pathway using deforolimus in cancer therapy

By Mahalingam Devalingam   Sankhala Kamalesh   Mita Alain   Giles Francis J   Mita Monica M  

Future Oncology, Vol. 5, Iss. 3, 2009-04 ,pp. : 291-303

Future Medicine

Access to resources Recommend Favorite

Well-differentiated pancreatic islet cell carcinoma: Is there reversibility in mTOR inhibitor resistance?

By Walter Thomas   Scoazec Jean-Yves   Couderc Christophe   Forestier Julien   Roche Colette   Chayvialle Jean-Alain   Lombard-Bohas Catherine  

Acta Oncologica, Vol. 50, Iss. 5, 2011-06 ,pp. : 731-732

Informa Healthcare

Access to resources Recommend Favorite

Significance of mTOR Signaling and Its Inhibitor Against Cancer Stem-Like Cells in Colorectal Cancer

By Cai Zerong   Ke Jia   He Xiaosheng   Yuan Ruixue   Chen Yufeng   Wu Xianrui   Wang Lei   Wang Jianping   Lan Ping   Wu Xiaojian  

Annals of Surgical Oncology, Vol. 21, Iss. 1, 2014-01 ,pp. : 179-188

Springer Publishing Company

Access to resources Recommend Favorite

Role of mTOR inhibitor in cholangiocarcinoma cell progression

By        

Oncology Letters, Vol. 7, Iss. 3, 2014-01 ,pp. : 854-860

Spandidos Publications

Access to resources Recommend Favorite

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

By Pal Sumanta  

Targeted Oncology, Vol. 6, Iss. 1, 2011-03 ,pp. : 5-16

Springer Publishing Company

Access to resources Recommend Favorite